A Phase 3 interventional study of Clopidogrel (SR25990) and placebo in Heart Defects, Congenital, sponsored by Sanofi. Completed at 31 sites in 31 countries. Open to participants aged Up to 92 Days. Per ClinicalTrials.gov, last updated 2014-10-24.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 356 studies in Heart Defects, Congenital with a site in United States — 66 open to participants now, 87 under way, 4 of them phase 3. Heart Defects, Congenital · United States.
Among the 356 studies in Heart Defects, Congenital with a site in United States, this one is the 4th largest by enrollment of the 184 interventional ones that give a count, is one of 16 that started in 2006, is one of 19 in phase 3, and was the 44th registered.
992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.
Browse Heart Defects, Congenital studies →66 of the 356 studies in Heart Defects, Congenital with a site in United States are open now. Recruiting first, the newest first:
University of Nebraska · Sites in United States
Ages 1 mo–3 yrs
Le Bonheur Children's Hospital · Sites in United States
Ages 0 mo–12 mo
Carelon Research · Sites in United States
Ages 18+
Carelon Research · Sites in United States
Ages 18+
The Cleveland Clinic · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 154 Heart Defects, Congenital studies recruiting now, 67 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 110 take children under 18; 25 take healthy volunteers.
This study: Up to 92 Days · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
356 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 33 · Phase 3 25 · Phase 4 9
First in 1980; this study’s year is marked. 16 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 906 is above the median of 60 across 508 interventional studies indexed under Heart Defects, Congenital.
Median enrollment 50 across the 184 interventional studies, 72 across the 167 observational. Of the 240 that completed or were terminated, 62 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 356 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Sanofi has 3 studies filed under Heart Defects, Congenital — fewer than ten, so there is no comparison to draw.
31 of the studies in Heart Defects, Congenital with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04216927Phase 3Children's Hospital Medical Center, CincinnatiNO During CPB in Neonates to Reduce Risk of AKI | 2027-06-30 |
| NCT05077774Medtronic CardiovascularHarmony TPV Post-Approval Study | 2026-11 |
| NCT05687292Boston Children's HospitalApplication of a Clinical Decision Support System to Reduce Mechanical Ventilation Duration After Cardiac Surgery in Children | 2026-11-18 |
| NCT07559253University of Wisconsin, MadisonImplementation of an Accessible Healthcare Model (ACHD STRONG): Comparing Nurse and Physician Lead Healthcare Transition Education in a RE-AIM Framework | 2026-11-30 |
| NCT04236479Catherine BollardMesenchymal Stromal Cells for Infants With Congenital Heart Disease (MedCaP) | 2026-12 |
Add all 31 to your calendar (.ics) → With an account.
Among the 356 studies in Heart Defects, Congenital with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Contemporary management of cyanotic congenital heart disease includes three stages of surgery. Incidence of shunt thrombosis and death between the two first stages of palliation remains important.
The primary objective of the study is to evaluate the efficacy of Clopidogrel 0.2 mg/kg/day for the reduction of all cause mortality and shunt related morbidity in neonates or infants with cyanotic congenital heart disease palliated with a systemic-to-pulmonary artery shunt (e.g. modified Blalock Taussig Shunt [BTS]).
The secondary objective was to assess the safety of Clopidogrel in the study population.
In this event-driven study, participants were to be randomized and treated as soon as possible after shunt placement. They were then to be treated and followed until the primary endpoint criteria was reached i.e. (shunt thrombosis, the next surgical procedure for correction of the congenital heart disease or death) or one year of age or the common study-end-date, which ever came first.
The common study-en-date was defined as the date when it was projected that 172 participants would have reached the primary endpoint criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: placebo
Drug: Clopidogrel (SR25990)
Form: reconstituted solution using Clopidogrel powder Route: oral or enteric Frequency: once daily Dose: daily dose adjusted for weight
Also known as: Plavix
Form: reconstituted solution using matching placebo powder Route: oral or enteric Frequency: once daily Dose: daily dose adjusted for weight
Number of Participants Reaching Primary Endpoint Criteria (First Occurrence of Death / Shunt Thrombosis / Cardiac Procedure < 120 Days Considered of Thrombotic Nature)
The primary endpoint was the first occurence of any of the following events: Death (including heart transplant); Shunt thrombosis requiring intervention; Hospitalization for bi-directional Glenn procedure or any cardiac related intervention prior to 120 days of age following an event or a shunt narrowing considered to be of thrombotic nature by the blinded adjudication committee. Only the first event was counted.
Time frame: Median follow-up of 5.8 months (up to a maximum of 12 months after randomization)
Number of Participants With Bleeding Events
Bleeding events spanning from signature of the Informed Consent Form up to the last visit were collected as for any Adverse Event. The 'on-treatment' period was defined as the period from randomization up until 28 days after treatment discontinuation or final follow-up visit, whichever came first, and participants who experienced bleeding events during that period were counted.
Time frame: From randomization up to 28 days after treatment discontinuation or final follow-up visit, whichever comes first
Number of Participants According to Bleeding Type/Etiology
For all reported bleeding events, the type and the etiology of the bleeding event were collected. Participants who experienced bleeding events during the 'on-treatment period' were counted by bleeding type and etiology. Participants who had multiple bleedings could be counted several times.
Time frame: From randomization up to 28 days after treatment discontinuation or final follow-up visit, whichever comes first
Recruitment was initially planned with a minimum of 490 participants anticipating that it would continue until a total of 172 participants reaching primary endpoint criteria is achieved. Finally 906 participants were enrolled and randomized between November 2006 and October 2009 in 134 sites in 31 countries. Actual median follow-up was 5.8 months.
| Milestone | Placebo | Clopidogrel 0.2 mg/kg/Day |
|---|---|---|
| Started | 439 | 467 |
| Treated | 436 | 464 |
| Completed treatment | 356 | 352 |
| Completed | 433 | 459 |
| Not completed | 6 | 8 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Parent(s)/guardian(s)'s request | 4 | 7 |
The primary endpoint was the first occurence of any of the following events: Death (including heart transplant); Shunt thrombosis requiring intervention; Hospitalization for bi-directional Glenn procedure or any cardiac related intervention prior to 120 days of age following an event or a shunt narrowing considered to be of thrombotic nature by the blinded adjudication committee. Only the first event was counted.
| participants | Placebo | Clopidogrel 0.2 mg/kg/Day |
|---|---|---|
| Death / Shunt Thrombosis / Cardiac Procedure | 90 | 89 |
| - Death | 60 | 51 |
| - Shunt thrombosis | 21 | 26 |
| - Cardiac procedure <120 days of thrombotic nature | 9 | 12 |
Bleeding events spanning from signature of the Informed Consent Form up to the last visit were collected as for any Adverse Event. The 'on-treatment' period was defined as the period from randomization up until 28 days after treatment discontinuation or final follow-up visit, whichever came first, and participants who experienced bleeding events during that period were counted.
| participants | Placebo | Clopidogrel 0.2 mg/kg/Day |
|---|---|---|
| Any bleeding event | 88 | 87 |
| - Serious | 32 | 30 |
| - Serious with an outcome of death | 1 | 1 |
| - Leading to permanent treatment discontinuation | 9 | 9 |
For all reported bleeding events, the type and the etiology of the bleeding event were collected. Participants who experienced bleeding events during the 'on-treatment period' were counted by bleeding type and etiology. Participants who had multiple bleedings could be counted several times.
| participants | Placebo | Clopidogrel 0.2 mg/kg/Day |
|---|---|---|
| Spontaneous | 60 | 56 |
| Post-traumatic | 6 | 11 |
| Puncture (vascular access site) | 19 | 9 |
| Surgical | 10 | 17 |
Collected over All Adverse Events (AE) regardless of seriousness or relationship to the drug, spanning from signature of the Informed Consent Form up to the last visit were collected.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 196/436 (45%) | 96/436 (22%) |
| Clopidogrel 0.2mg/kg/Day | — | 234/464 (50.4%) | 107/464 (23.1%) |
| Event | Placebo | Clopidogrel 0.2mg/kg/Day |
|---|---|---|
| GASTROENTERITISInfections and infestations | 14/436 | 24/464 |
| CYANOSISCardiac disorders | 9/436 | 24/464 |
| PNEUMONIAInfections and infestations | 9/436 | 21/464 |
| BRONCHIOLITISInfections and infestations | 12/436 | 15/464 |
| HYPOXIARespiratory, thoracic and mediastinal disorders | 11/436 | 14/464 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 13/436 | 11/464 |
| OXYGEN SATURATION DECREASEDInvestigations | 10/436 | 11/464 |
| SEPSISInfections and infestations | 4/436 | 8/464 |
| POST PROCEDURAL HAEMORRHAGEInjury, poisoning and procedural complications | 4/436 | 8/464 |
| HAEMATOCHEZIAGastrointestinal disorders | 7/436 | 2/464 |
| Event | Placebo | Clopidogrel 0.2mg/kg/Day |
|---|---|---|
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 53/436 | 60/464 |
| VOMITINGGastrointestinal disorders | 18/436 | 32/464 |
| NASOPHARYNGITISInfections and infestations | 24/436 | 21/464 |
| DIARRHOEAGastrointestinal disorders | 20/436 | 24/464 |
| Age, Continuous(days) | Placebo | Clopidogrel 0.2 mg/kg/Day | Total |
|---|---|---|---|
| Mean | 36.0 ± 22.5 | 36.1 ± 22.3 | 36.1 ± 22.4 |
| Age, Customized(participants) | Placebo | Clopidogrel 0.2 mg/kg/Day | Total |
|---|---|---|---|
| ≤ 30 days | 223 | 238 | 461 |
| 30 (<) - 92 days | 216 | 229 | 445 |
| Sex: Female, Male(Participants) | Placebo | Clopidogrel 0.2 mg/kg/Day | Total |
|---|---|---|---|
| Female | 185 | 198 | 383 |
| Male | 254 | 269 | 523 |
| Region of Enrollment(participants) | Placebo | Clopidogrel 0.2 mg/kg/Day | Total |
|---|---|---|---|
| United States | 90 | 88 | 178 |
| Portugal | 10 | 10 | 20 |
| Taiwan | 12 | 10 | 22 |
| Hong Kong | 1 | 0 | 1 |
| Thailand | 2 | 3 | 5 |
| Spain | 16 | 14 | 30 |
| Israel | 3 | 4 | 7 |
| Russian Federation | 13 | 15 | 28 |
| Italy | 20 | 19 | 39 |
| India | 20 | 27 | 47 |
| France | 11 | 10 | 21 |
| Malaysia | 5 | 4 | 9 |
| Denmark | 3 | 3 | 6 |
| South Africa | 13 | 13 | 26 |
| Netherlands | 2 | 4 | 6 |
| China | 10 | 11 | 21 |
| Korea, Republic of | 3 | 2 | 5 |
| Finland | 2 | 1 | 3 |
| United Kingdom | 16 | 16 | 32 |
| Egypt | 4 | 6 | 10 |
| Hungary | 9 | 9 | 18 |
| Mexico | 32 | 37 | 69 |
| Canada | 5 | 6 | 11 |
| Argentina | 24 | 28 | 52 |
| Brazil | 31 | 34 | 65 |
| Belgium | 9 | 12 | 21 |
| Poland | 3 | 7 | 10 |
| Singapore | 2 | 2 | 4 |
| Germany | 54 | 59 | 113 |
| Norway | 8 | 8 | 16 |
| Sweden | 6 | 5 | 11 |
| Weight(kilograms (kg)) | Placebo | Clopidogrel 0.2 mg/kg/Day | Total |
|---|---|---|---|
| Mean | 3.5 ± 0.7 | 3.4 ± 0.7 | 3.5 ± 0.7 |
| Height(Centimeters (cm)) | Placebo | Clopidogrel 0.2 mg/kg/Day | Total |
|---|---|---|---|
| Mean | 51.8 ± 4.6 | 51.4 ± 4.4 | 51.6 ± 4.5 |
| Type of systemic-to-pulmonary artery shunt palliation(participants) | Placebo | Clopidogrel 0.2 mg/kg/Day | Total |
|---|---|---|---|
| Modified Blalock Taussig Shunt with Norwood | 51 | 62 | 113 |
| Modified Blalock Taussig Shunt without Norwood | 252 | 257 | 509 |
| Sano procedure with Norwood | 54 | 60 | 114 |
| Sano procedure without Norwood | 2 | 5 | 7 |
| Central shunt | 38 | 40 | 78 |
| Stent of ductus arteriosus | 42 | 42 | 84 |
| Not applicable | 0 | 1 | 1 |
| Shunt on cardiopulmonary bypass(participants) | Placebo | Clopidogrel 0.2 mg/kg/Day | Total |
|---|---|---|---|
| Yes | 177 | 194 | 371 |
| No | 262 | 273 | 535 |
2 further baseline measures are reported on the registry.
The record gives a start of Nov 2006, a primary completion of Feb 2010 and a completion of Feb 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2011, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Clopidogrel